Results 31 to 40 of about 115,050 (245)
Presence of the Transmembrane Protein Neuropilin in Cytokine-induced Killer Cells
Anticancer Research, 2020 Cytokine-induced killer (CIK) cells are a heterogenous population of immune cells showing promising applications in immunotherapeutic cancer treatment. Neuropilin (NRP) proteins have been proven to play an important role in cancer development and prognosis.
Diez Garcia De Olalla E. V. +5 more
openaire +3 more sources
Enhancing cytokine-induced killer cell therapy of multiple myeloma [PDF]
Experimental Hematology, 2013 Cytokine-induced killer (CIK) cells are in clinical testing against various tumor types, including multiple myeloma. In this study, we show that CIK cells have activity against subcutaneous and disseminated models of human myeloma (KAS-6/1), which can be enhanced by infecting the CIK cells with an oncolytic measles virus (MV) or by pretreating the ...
Chunsheng, Liu +4 more
openaire +2 more sources
Treatment of multiple solitary plasmacytomas with cytokine-induced killer cells [PDF]
Cytotherapy, 2014 Currently available treatment methods for advanced plasmacytoma include surgery, chemotherapy, radiotherapy, immunomodulatory agents, hematopoietic stem cell transplantation and donor lymphocyte infusion. We report a case of advanced refractory multiple solitary plasmacytomas in a 68-year-old Asian man with multiple bone lesions, in whom autologous ...
Bo, Yang +6 more
openaire +2 more sources
Medicine, 2018 Immunotherapy is emerging as a new treatment strategy for gastric cancer(GC). However, the efficacy and safety of this technique remain unclear. This meta-analysis aimed to assess the effect of cytokine-induced killer cell (CIK)/dendritic cell-cytokine-induced killer cell (DC-CIK) treatment for GC after surgery.Hazard ratio (HR), overall survival (OS ...
Wang, Xiang +7 more
openaire +2 more sources
Haematologica, 2013 Invariant natural killer T cells recognize glycolipid antigens such as α-galactosylceramide presented by CD1d. In preclinical models of B-cell malignancies, α-galactosylceramide is an adjuvant to tumor vaccination, enhancing tumor-specific T-cell ...
Robert Weinkove +4 more
doaj +1 more source
OncoTargets and Therapy, 2017 Immunotherapy based on cytokine-induced killer cells or combination of dendritic cells and cytokine-induced killer cells (CIK/DC-CIK) showed promising clinical outcomes for treating esophageal cancer (EC). However, the clinical benefit varies among previous studies.
Yan Liu +7 more
openaire +4 more sources
Frontiers in Immunology, 2015 We present the first clinical evidence of advanced squamous non-small cell lung cancer with severe thrombocytopenia showing dramatic improvement after first-line treatment with pembrolizumab plus cytokine-induced killer cells.
Zhenzhen eHui +4 more
doaj +1 more source
Clinical & Translational Immunology, 2021 Objectives Although axitinib has achieved a preferable response rate for advanced renal cell carcinoma (RCC), patient survival remains unsatisfactory. In this study, we evaluated the efficacy and safety of a combination treatment of axitinib and a low ...
Meng‐Jia Song +29 more
doaj +1 more source
Frontiers in Immunology, 2022 Breast cancer is one of the most common cancers in women. Triple-negative breast cancer (TNBC) has a significantly worse prognosis due to the lack of endocrine receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal ...
Xinyi Yang +20 more
doaj +1 more source
Efficacy of cytokine-induced killer cells targeting CD40 and GITR. [PDF]
Oncol Lett, 2019 Since the publication of a novel protocol in 1991, cytokine-induced killer (CIK) cells have shown promising results in the treatment against neoplastic diseases. Despite ongoing preclinical and clinical studies, CIK cell treatment in the context of human monoclonal antibodies targeting tumor-necrosis factor receptors remains overlooked.
Biederbick KD, Schmidt-Wolf IGH.
europepmc +4 more sources